Skip to main content

Table 1 Demographic characteristics of the 34 patients with EPE

From: Incidence, aetiology and clinical features of eosinophilic pleural effusion: a retrospective study

No

Age (y)

Sex

Peripheral blood

Pleural effusion

Diagnosis

WBC (× 109/L)

LYM (× 109/L)

EO (× 109/L)

WBC (× 109/L)

EO (%)

RBC (× 106/L)

LDH (U/L)

ADA (U/L)

GLU (mmol/L)

Protein (g/L)

CEA (ng/mL)

1

48

M

4.7

0.3

0.6

4.4

13.5

1466

128

6.7

3.02

43.2

4.80

PPI

2

29

M

12.7

1.6

0.3

5.8

30.2

1703

587

19.1

3.19

43.1

1.74

PPI

3

63

F

16.7

1.8

5.8

8.0

22.5

449

667

10.8

5.95

47.4

0.30

PPI

4

48

M

11.3

1.2

0.6

4.8

19.0

2200

189

2.8

7.79

39.8

1.67

IPE

5

49

M

4.6

1.4

0.4

3.8

15.2

5277

201

24.0

5.15

35.6

4.31

IPE

6

45

M

8.6

0.7

0.4

4.7

21.2

3251

234

20.0

4.84

43.2

3.34

IPE

7

52

F

8.7

1.5

0.3

7.4

18.9

549

321

17.0

4.97

34.2

2.67

IPE

8

49

F

10.4

1.1

0.8

5.5

12.4

1583

214

19.9

4.40

32.8

3.40

IPE

9

35

F

5.7

1.4

0.3

6.6

46.5

5262

421

20.4

5.61

49.6

0.95

PPE

10

25

M

9.7

2.4

0.7

12.9

67.5

1232

365

6.5

5.45

53.4

1.54

PPE

11

67

F

14.6

0.5

0

4.1

19.2

5637

145

1.7

8.02

33.9

2.15

PPE

12

46

M

8.1

0.9

0.1

2.6

12.8

4788

558

44.7

5.68

53.4

1.18

TPE

13

83

F

6.5

1.5

0

0.4

15.7

4581

130

2.1

6.90

27.5

1.67

HR-PE

14

33

F

7.6

0.6

0.1

0.8

15.3

186

116

0.1

5.48

28.8

1.32

CTD-PE

15

66

M

5.2

1.2

0

0.3

25.5

2,986,738

90

1.8

7.45

37.5

1.53

Haemothorax

16

70

M

5.2

0.6

0

2.4

11.6

20,185

111

3.8

6.37

32.4

2.08

Pulmonary embolism

17

70

M

4.9

0.9

0.1

3.2

23.5

2339

1402

13.2

6.11

39.5

148.20

MPE

18

57

M

9.9

2.3

1

1.1

55.0

15,319

712

10.3

6.66

48.2

162.20

MPE

19

74

M

7.7

1.2

1.5

0.3

11.0

192

326

3.1

5.99

35.2

49.04

MPE

20

45

M

6.8

1.1

0.3

1.3

11.6

7422

352

7.2

6.34

53.7

81.15

MPE

21

44

F

6.8

1.2

0.2

0.1

12.5

2573

403

4.2

5.80

60.7

2087.0

MPE

22

88

M

8.6

2.5

0.4

0.9

12.0

4951

563

3.3

4.52

49.3

384.50

MPE

23

47

F

4.9

1.1

0.2

1.5

10.5

13,366

172

3.1

7.52

40.6

289.70

MPE

24

58

M

14.8

1.1

0.1

0.4

23.5

5052

310

7.8

5.57

44.3

339.40

MPE

25

81

M

21.4

1.9

0.1

1.0

13.5

2859

182

7.6

6.04

182.9

2.60

MPE

26

59

F

5.1

1.2

0.2

0.2

14.5

25,654

424

4.2

5.19

40.5

0.94

MPE

27

61

M

6.2

0.9

0

0.6

11.5

5787

215

7.0

7.24

53.9

17.39

MPE

28

55

F

8.8

2.2

0.2

0.2

10.0

7097

217

3.0

4.44

40.2

1.27

MPE

29

67

F

9.5

1.5

0.3

4.5

11.0

320,000

327

4.2

8.34

52.0

10.97

MPE

30

76

M

6.4

1.0

0.1

1.1

10.5

3000

232

4.0

8.01

42.9

4.07

MPE

31

56

F

3.2

0.6

0.5

2.2

31.0

1752

265

8.1

7.83

51.8

1.89

MPE

32

44

M

11.2

1.5

0.6

0.4

22.5

12,315

209

4.0

9.77

49.7

0.46

MPE

33

57

F

9.0

1.8

0.8

7.7

63.0

216,195

1126

29.3

4.32

62.3

0.91

MPE

34

71

M

8.11

0.9

0.5

6.5

24.0

91,620

645

27.6

6.48

49.4

0.99

MPE

  1. Abbreviations: EPE eosinophilic pleural effusion, WBC white blood cell, LYM lymphocyte, EO eosinophil, RBC red blood cell, LDH lactate dehydrogenase, ADA adenosine deaminase, GLU glucose, CEA carcinoembryonic antigen, PPI pleural parasitic infestation, IPE idiopathic pleural effusion, PPE parapneumonic effusion, TPE tuberculous pleural effusion, HR-PE heart related pleural effusion, CTD-PE Connective tissue diseases- pleural effusion, MPE malignant pleural effusion